Apogee Therapeutics, Inc. (NASDAQ:APGE) Shares Purchased by Deutsche Bank AG

Deutsche Bank AG lifted its position in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) by 50.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 31,739 shares of the company's stock after buying an additional 10,709 shares during the quarter. Deutsche Bank AG owned approximately 0.07% of Apogee Therapeutics worth $1,438,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Driehaus Capital Management LLC boosted its position in Apogee Therapeutics by 2.8% during the fourth quarter. Driehaus Capital Management LLC now owns 2,605,310 shares of the company's stock worth $118,021,000 after acquiring an additional 71,703 shares during the last quarter. Cubist Systematic Strategies LLC lifted its stake in shares of Apogee Therapeutics by 8.6% during the 4th quarter. Cubist Systematic Strategies LLC now owns 91,213 shares of the company's stock worth $4,132,000 after purchasing an additional 7,236 shares during the period. BNP Paribas Financial Markets acquired a new stake in shares of Apogee Therapeutics during the fourth quarter worth $219,000. Ameriprise Financial Inc. purchased a new stake in shares of Apogee Therapeutics in the fourth quarter valued at $259,000. Finally, Allostery Investments LP acquired a new position in Apogee Therapeutics in the fourth quarter valued at $4,530,000. 79.04% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have commented on APGE. Citigroup began coverage on Apogee Therapeutics in a report on Thursday, March 13th. They issued a "buy" rating and a $95.00 price target for the company. Guggenheim restated a "buy" rating on shares of Apogee Therapeutics in a report on Monday, February 10th. Finally, Wedbush reaffirmed an "outperform" rating and set a $90.00 price target on shares of Apogee Therapeutics in a research report on Tuesday, March 11th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Apogee Therapeutics has a consensus rating of "Buy" and an average price target of $94.60.

Apogee Therapeutics Trading Up 3.5%

NASDAQ:APGE traded up $1.29 on Thursday, hitting $37.69. 389,323 shares of the stock were exchanged, compared to its average volume of 526,754. The stock has a fifty day moving average of $36.52 and a 200-day moving average of $40.06. The stock has a market cap of $1.74 billion, a PE ratio of -15.57 and a beta of 1.70. Apogee Therapeutics, Inc. has a fifty-two week low of $26.20 and a fifty-two week high of $63.50.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.95) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.19) by $0.24. As a group, analysts predict that Apogee Therapeutics, Inc. will post -3.09 earnings per share for the current year.

Insider Transactions at Apogee Therapeutics

In other Apogee Therapeutics news, insider Carl Dambkowski sold 3,860 shares of the stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $36.22, for a total value of $139,809.20. Following the completion of the sale, the insider now owns 247,173 shares of the company's stock, valued at $8,952,606.06. This trade represents a 1.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Michael Thomas Henderson sold 10,000 shares of Apogee Therapeutics stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $30.15, for a total transaction of $301,500.00. Following the sale, the chief executive officer now owns 1,292,987 shares in the company, valued at $38,983,558.05. This represents a 0.77% decrease in their position. The disclosure for this sale can be found here. Insiders sold 18,175 shares of company stock valued at $587,191 over the last 90 days. Corporate insiders own 42.77% of the company's stock.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.